These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 15486559)
1. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559 [TBL] [Abstract][Full Text] [Related]
2. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289 [TBL] [Abstract][Full Text] [Related]
3. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563 [TBL] [Abstract][Full Text] [Related]
4. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880 [TBL] [Abstract][Full Text] [Related]
5. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Carles-Kinch K; Kilpatrick KE; Stewart JC; Kinch MS Cancer Res; 2002 May; 62(10):2840-7. PubMed ID: 12019162 [TBL] [Abstract][Full Text] [Related]
6. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165 [TBL] [Abstract][Full Text] [Related]
7. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Wykosky J; Gibo DM; Stanton C; Debinski W Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188 [TBL] [Abstract][Full Text] [Related]
8. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Guo H; Miao H; Gerber L; Singh J; Denning MF; Gilliam AC; Wang B Cancer Res; 2006 Jul; 66(14):7050-8. PubMed ID: 16849550 [TBL] [Abstract][Full Text] [Related]
9. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680 [TBL] [Abstract][Full Text] [Related]
10. [Adenovirus-mediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro]. Kong H; Huang ZH; Li Q; Yang LC; Yu JL; Li Z Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):907-10. PubMed ID: 18583225 [TBL] [Abstract][Full Text] [Related]
11. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. Pratt RL; Kinch MS Mol Cancer Res; 2003 Dec; 1(14):1070-6. PubMed ID: 14707290 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358 [TBL] [Abstract][Full Text] [Related]
13. Differential EphA2 epitope display on normal versus malignant cells. Coffman KT; Hu M; Carles-Kinch K; Tice D; Donacki N; Munyon K; Kifle G; Woods R; Langermann S; Kiener PA; Kinch MS Cancer Res; 2003 Nov; 63(22):7907-12. PubMed ID: 14633720 [TBL] [Abstract][Full Text] [Related]
14. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo. Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823 [TBL] [Abstract][Full Text] [Related]
15. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Nasreen N; Mohammed KA; Lai Y; Antony VB Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899 [TBL] [Abstract][Full Text] [Related]
16. Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP-2 gene transfer. Lee YK; So IS; Lee SC; Lee JH; Lee CW; Kim WM; Park MK; Lee ST; Park DY; Shin DY; Park CU; Kim YS J Gene Med; 2005 Feb; 7(2):145-57. PubMed ID: 15546163 [TBL] [Abstract][Full Text] [Related]
17. A conditional feedback loop regulates Ras activity through EphA2. Macrae M; Neve RM; Rodriguez-Viciana P; Haqq C; Yeh J; Chen C; Gray JW; McCormick F Cancer Cell; 2005 Aug; 8(2):111-8. PubMed ID: 16098464 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675 [TBL] [Abstract][Full Text] [Related]